RBX2660, A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection, Is Safe and Effective: Results from a Randomised, Double-Blinded, Placebo-Controlled Trial

Robert Orenstein, DO, Mayo Clinic in Arizona, Phoenix, AZ

Robert Orenstein, DO, presentation at UEG 2016 on RBX2660 as safe and effective for recurrent Clostridium difficile infection image

Download this presentation (494 KB)

United European Gastroenterology Week
October 15-19, 2016, Vienna, Austria